Statistics

Total Visits

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients69

Select a period of time:

Number of views in the range

Views
Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients33

Views

Views
June 20250
July 202518
August 20250
September 20253
October 20253
November 20257
December 20252
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil16
United States7
Ecuador2
Chile1
Spain1
Ethiopia1
United Kingdom1
Honduras1
Kenya1
Senegal1
 

Top cities views

Views
Dallas2
São Paulo2
Brasília2
Anápolis1
Arujá1
Awasa1
Campinas1
Carangola1
Casimiro de Abreu1
Cuenca1